HMGB1 and central nervous system cancer: This follows release of HMGB1, a TLR2 agonist that activates dendritic cells and stimulates dendritic cells loaded with glioma antigens to migrate to the cervical lymph nodes to prime a systemic CD8+ T cytotoxic killing of glioma cells without causing brain toxicity and autoimmunity (193).